Arena Pharmaceuticals (ARNA)

$74.68 1.68 (2.20%)

18:44 EST ARNA Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 3.68B

PE Ratio -27.16

EPS -2.75

Volume (Avg. Vol.) 700,538

Day's Range 72.00 - 77.45

52-Week Range 32.95 - 90.19

Dividend & Yield N/A (N/A)

ARNA Stock Predictions, Articles, and Arena Pharmaceuticals News

From InvestorPlace
From the Web

8 Biotech Stocks to Watch After the Q2 Earnings Season

By Chris Lau, InvestorPlace Contributor Aug 20, 2019

Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.

5 Clinical-Stage Biotech Stocks to Buy

By Aaron Levitt, InvestorPlace Contributor Feb 25, 2019

There are plenty of potential in clinical-stage biotech stocks. Here are five with some wonderful catalysts.

Don’t Get Trapped by All the Hype Surrounding Cronos Stock

By James Brumley, InvestorPlace Feature Writer Feb 11, 2019

The big rally from Cronos Group stock has stalled, but too many investors are certain it's just a breather before another leg higher.

6 Stocks Set for Monster Growth in 2019

By Harriet Lefton, Writer, TipRanks Jan 28, 2019

Looking for stocks to buy now? These six companies are among the best stocks to invest in for their immaculate record from the Street's top analysts. Here's why:

Why Arena Pharmaceuticals Stock Is Soaring Today

By William White, InvestorPlace Writer Nov 15, 2018

Arena Pharmaceuticals stock was soaring Thursday on news of a license deal with United Therapeutics (UTHR) for ralinepag.

Intercept Pharmaceuticals Inc (ICPT) Stock Dives on Drug Warning

By William White, InvestorPlace Writer Sep 12, 2017

Intercept Pharmaceuticals (ICPT) stock took a hit on Tuesday following the release of a drug warning concerning its Ocaliva.

3 Stocks to Watch on Tuesday: Snap Inc (SNAP), Barracuda Networks Inc (CUDA) and Arena Pharmaceuticals, Inc. (ARNA)

By Karl Utermohlen, InvestorPlace Writer Jul 11, 2017

Snap (SNAP) continues slumping below its IPO price Tuesday and Arena Pharmaceuticals (ARNA) rockets ahead on trial data, while Barracuda Networks (CUDA) slides on earnings.

5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio

By Zacks Investment Research May 25, 2017

VIVUS is a biopharmaceutical company developing and commercializing innovative, next-generation therapies. Here's why VVUS stock is a must

3 Stocks to Watch on Wednesday: Bank of America Corp (BAC), Arena Pharmaceuticals, Inc. (ARNA) and Fogo De Chao Inc (FOGO)

By Karl Utermohlen, InvestorPlace Writer Mar 15, 2017

Bank of America (BAC) anxiously awaits a Fed decision on Wednesday, Arena Pharmaceuticals (ARNA) rockets higher and Fogo de Chao (FOGO) carves out some gains.

26 Biotechnology Stocks to Sell Now

By Portfolio Grader Sep 19, 2016

The ratings of 26 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

23 Biotechnology Stocks to Sell Now

By Portfolio Grader Sep 12, 2016

The overall ratings of 23 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

22 Biotechnology Stocks to Sell Now

By Portfolio Grader Jul 11, 2016

This week, 22 Biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

19 Biotechnology Stocks to Sell Now

By Portfolio Grader Jul 4, 2016

The overall ratings of 19 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

3 Stocks to Watch on Friday: Arena Pharmaceuticals, Inc. (ARNA), Micron Technology, Inc. (MU) and Tesla Motors Inc (TSLA)

By Karl Utermohlen, InvestorPlace Writer Jul 1, 2016

Tesla (TSLA) shares fell on a self-driving accident, Arena Pharmaceuticals (ARNA) will cut more than half its workforce and Micron (MU) misses revenue estimates.